Clinical Trials for Biosimilars Could Be Shortened, Study Finds

A new study indicates biosimilar trials remained consistent from 4-6 months through 12 months, which investigators suggest indicates these trials could be shortened without affecting safety and efficacy profiles.

Related Keywords

Germany ,Helena Guillen ,Nadine Kirsch Stefan ,Linkedin ,Paul Ehrlich Institute In Langen ,Paul Ehrlich Institute ,